Drug Trial Radar · NCT07842185
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,192
Planned (sponsor's estimate)
Start
Dec 19, 2026
Primary completion
Dec 30, 2030
Study completion May 8, 2031
Sponsor
- Lead sponsor
- Xinqiao Hospital of ChongqingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Affiliated Ganzhou Hospital of Nanchang University
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute ischemic stroke is a leading cause of disability and mortality among dults in China. Although intravenous thrombolysis serves as first-line reperfusion therapy, nearly half of patients fail to achieve vascular recanalization. The reocclusion rate ranges from 14% to 34%, and many patients are left with residual neurological deficits. Early antiplatelet therapy initiated after thrombolysis may sustain persistent reperfusion and improve prognosis. However, current guidelines generally recommend delaying antiplatelet treatment until 24 hours post-thrombolysis due to bleeding risks, and direct evidence for the optimal initiation timing remains lacking. Tirofiban is a rapidly acting, short-half-life, reversible glycoprotein IIb/IIIa receptor antagonist. Previous studies indicate its potential benefits and acceptable safety when administered after intravenous thrombolysis. This is a multicenter, open-label, endpoint-blinded randomized controlled trial. A total of 1192 non-cardioembolic patients without large or medium vessel occlusion and with residual neurological deficits (NIHSS ≥4) after thrombolysis will be enrolled. Participants will be randomly allocated to the tirofiban 24-hour group, tirofiban 48-hour group. The primary outcome is the proportion of patients with excellent functional outcome defined as modified Rankin Scale (mRS) score 0-1 at 90 days. Symptomatic intracranial hemorrhage and neurological outcomes will also be evaluated. The study aims to determine the optimal duration of tirofiban treatment after thrombolysis and provide high-level evidence for precise interventions in the acute phase of stroke.
Conditions
- Acute Ischemic Stroke
Interventions
Tirofiban InjectionDrug
Intravenous infusion of tirofiban will be initiated after intravenous thrombolysis and continued for 24 hours. The dosage regimen follows the trial protocol.
Tirofiban InjectionDrug
Intravenous infusion of tirofiban will be initiated after intravenous thrombolysis and continued for 48 hours. The dosage regimen follows the trial protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with mRS 0-1 at 90 daysTime frame: 90 days after randomization
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Taihe County People's Hospital
Fuyang, Anhui, China
Longyan First Hospital of Fujian Medical University
Longyan, Fujian, China
Xiangtan Central Hospital (The Affiliated Hospital of Hunan University)
Xiangtan, Hunan, China
Ganzhou People's Hospital
Ganzhou, Jiangxi, China
Xingguo People's Hospital, Xinguo Hospital of Gannan Medical University
Ganzhou, Jiangxi, China
Jingdezhen First People's Hospital
Jingdezhen, Jiangxi, China
The First People's Hospital of Jingdezhen City
Jingdezhen, Jiangxi, China
Jiujiang First People's Hospital
Jiujiang, Jiangxi, China
Dalian Central Hospital
Dalian, Liaoning, China
The First People's Hospital of Mianyang (Mianyang 404 Hospital)
Mianyang, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.